Randomized controlled double ‐blinded clinical trial of the effect of bevacizumab injection in the management of epistaxis in HHT patients undergoing surgical cauterization

ConclusionThe addition of a single treatment of submucosal bevacizumab may be associated with additional clinically meaningful benefit for up to 4 months when compared to electrocautery alone.This article is protected by copyright. All rights reserved

Source: International Forum of Allergy and Rhinology - January 6, 2022 Category: Allergy & Immunology Authors: Ashoke R. Khanwalkar, Aakanksha Rathor, Amelia K. Read, Yifei Ma, Peter H. Hwang Tags: ORIGINAL ARTICLE Source Type: research